Next-Generation Antibody Therapeutics Market Research Report

Next-Generation Antibody Therapeutics
Market (Size of $1,328 million in 2014) to
Witness 44% CAGR during 2015 – 2020
[email protected]
Next-Generation Antibody Therapeutics Market
The global next generation antibody therapeutics market was valued at
$1,328.3 million in 2014 and it is expected to grow at a CAGR of about 44%
during the period 2015 - 2020. The global next-generation antibody
therapeutics market is growing due to increasing popularity of antibodydrug conjugate (ADC) and increasing number of collaborations for R&D in
next-generation antibody therapeutics. In addition, growing prevalence of
chronic diseases and increase in research and development investments by
various organizations for production of improved products further
encourages the growth of global next-generation antibody therapeutics
market. Furthermore, increase in healthcare expenditure and technological
advancements in antibody therapeutics have led to the development of
more efficient antibody therapeutics, which is resulting in increased
demand for next-generation antibody therapeutics.
Next-Generation Antibody Therapeutics Market
Based on technology, the Fc Engineered Antibodies market is expected to
witness the highest growth (CAGR of 11%) during the forecast period.
Among the therapeutic areas, the oncology segment led the global nextgeneration antibody therapeutics market in 2014, with the largest market
size, but the autoimmune/inflammatory is expected to see the fastest
growth of 46.4% CAGR, during the period 2015 – 2020.
The information and data in the publication “Global Next-Generation
Antibody Therapeutics Market Size, Share, Development, Growth and
Demand Forecast to 2020” represent the research and analysis of data from
various primary and secondary sources. The bottom-up approach has been
used to calculate the global EHR systems market by type and by therapeutic
area. The market numbers for countries are obtained through top-down
approach. P&S Market Research analysts and consultants interact with
leading companies of the concerned domain to substantiate every single
data presented in this report. The company bases its primary research on
discussions with prominent professionals and analysts in the industry, aided
by informed and detailed online and offline research.
Next-Generation Antibody Therapeutics Market
Governments of various countries are involved in taking initiatives for
improving healthcare facilities, and making next-generation antibody
therapeutics affordable. This is increasing the demand for next-generation
antibody therapeutics. The increasing global gross domestic product (GDP)
and growing healthcare expenditure have created a positive impact on the
growth of the next-generation antibody therapeutics market. Also, in
comparison to traditional antibodies, the next-generation antibody
therapeutics is more effective in the treatment of various diseases, such as
cancer, autoimmune disorders, and inflammatory diseases. This is attracting
various pharmaceutical and biotechnology companies to increase their
investment in the R&D of next-generation antibody therapeutics.
Next-Generation Antibody Therapeutics Market
However, certain restraints such as high cost of next-generation antibody
therapeutics, stringent regulatory requirements and time-consuming
approval process for new drugs are hindering the market growth. North
America next-generation antibody therapeutics market is expected to
witness the fastest growth of CAGR 46.2% globally, during the period 2015
– 2020.
The key companies operating in the global next-generation antibody
therapeutics market include Seattle Genetics Inc., F. Hoffmann-La Roche
Ltd, ImmunoGen Inc., Pfizer Inc., Amgen Inc., Biogen, Kyowa Hakko Kirin Co.
Ltd., Bristol-Myers Squibb Company, Xencor Inc., AstraZeneca PLC., Dyax
Corp., Takeda Pharmaceuticals Company Limited and Bayer AG.
Next-Generation Antibody Therapeutics Market
Download report sample at:
For information regarding permissions and other queries
Kindly write to:
[email protected]
US/Canada Toll-Free: 1-888-778-7886